Teva launches generic NuvaRing
Teva is introducing a generic version of Merck’s NuvaRing (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day.
The product is indicated for use by women to prevent pregnancy.
“The launch of a generic version of NuvaRing Vaginal Ring in the United States is an important addition to Teva’s generic portfolio,” said Christine Baeder, senior vice president, chief operating officer of Teva USA’s U.S. Generics. “With more than 40 generic products in our existing woman’s health portfolio, we are proud to add another accessible contraception option.”
Etonogestrel and ethinyl estradiol vaginal ring products have a market value of more than $837 million, according to IQVIA November 2020 data.